Denali Therapeutics Inc.
Denali Therapeutics Inc. (Nasdaq: DNLI) discovers and develops medicines for serious diseases, using its proprietary TransportVehicle (TV) technology to deliver large-molecule biotherapeutics across the blood-brain barrier and to tissues throughout the body. Its investigational therapies include enzyme,… From the company’s description.
In fiscal 2025, Denali Therapeutics Inc. reported a net loss of $512.54M. Operations used $412.60M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Denali Therapeutics Inc. does
In the company’s own words
Denali Therapeutics Inc. (Nasdaq: DNLI) discovers and develops medicines for serious diseases, using its proprietary TransportVehicle (TV) technology to deliver large-molecule biotherapeutics across the blood-brain barrier and to tissues throughout the body. Its investigational therapies include enzyme, oligonucleotide and antibody programs for lysosomal storage disorders and neurodegenerative diseases, as well as a small-molecule Parkinson’s disease candidate. The company’s leading programs target Hunter syndrome, Sanfilippo syndrome type A, frontotemporal dementia, Pompe disease, Alzheimer’s disease and Parkinson’s disease; it also pursues research in areas including oncology. Its portfolio is organized around Enzyme TV, Oligonucleotide TV and Antibody TV franchises. Denali collaborates with Takeda on a frontotemporal dementia program and with Biogen on a Parkinson’s disease program, among other partnerships, and has opened a clinical biomanufacturing facility to supply trials. Tividenofusp alfa for Hunter syndrome is under FDA priority review for accelerated approval, while DNL126 is in clinical development. Denali had five clinical-stage TV-enabled programs and more than ten preclinical programs. Its website is https://www.denalitherapeutics.com/.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- SOUTH SAN FRANCISCO, CA
- Fiscal year end
- December
- CIK
- 1714899
- SIC
- 2836
Financial performance, year by year
Fiscal 2018–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Denali Therapeutics Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Denali Therapeutics Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Denali Therapeutics Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Denali Therapeutics Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Denali Therapeutics Inc.'s last four quarterly filings that the numbers alone won't show?”